Florian Lordick
#138,160
Most Influential Person Now
Researcher
Florian Lordick's AcademicInfluence.com Rankings
Florian Lordickcomputer-science Degrees
Computer Science
#6462
World Rank
#6814
Historical Rank
Machine Learning
#2107
World Rank
#2134
Historical Rank
Artificial Intelligence
#2365
World Rank
#2405
Historical Rank
Database
#3548
World Rank
#3697
Historical Rank
Download Badge
Computer Science
Why Is Florian Lordick Influential?
(Suggest an Edit or Addition)Florian Lordick's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (2010) (5682)
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. (2010) (924)
- Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. (2010) (912)
- Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2016) (780)
- PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. (2007) (774)
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. (2013) (750)
- Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. (2010) (581)
- Gastric cancer (2020) (576)
- Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. (2006) (459)
- Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. (2004) (456)
- Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial (2018) (412)
- Oesophageal cancer (2017) (388)
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. (2020) (380)
- A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. (2006) (335)
- Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. (2003) (329)
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study (2019) (328)
- [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. (2011) (287)
- Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. (2006) (214)
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial (2017) (214)
- Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). (2014) (213)
- Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. (2009) (211)
- ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) (2016) (202)
- Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). (2009) (192)
- Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. (2009) (179)
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (2010) (175)
- Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. (2014) (172)
- 18F-FDG PET–Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial (2011) (172)
- Unmet needs and challenges in gastric cancer: the way forward. (2014) (168)
- Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG (2007) (163)
- Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. (2008) (159)
- TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG (2017) (156)
- Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer (2015) (155)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (142)
- TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG) (2015) (140)
- Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study (2008) (140)
- The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. (2004) (138)
- The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas (2006) (135)
- Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. (2012) (133)
- Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. (2006) (132)
- Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). (2009) (131)
- Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. (2007) (130)
- Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. (2013) (130)
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. (2011) (128)
- Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis (2007) (126)
- Her2/neu testing in gastric cancer: evaluating the risk of sampling errors (2012) (125)
- The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. (2011) (121)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (117)
- Clinical impact of tumour biology in the management of gastroesophageal cancer (2016) (116)
- Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555) (2012) (114)
- Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas (2009) (112)
- PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer (2007) (112)
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. (2011) (111)
- Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction (2007) (107)
- Optimal chemotherapy for advanced gastric cancer: is there a global consensus? (2014) (104)
- METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). (2015) (103)
- Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. (2008) (102)
- Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients (2008) (100)
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma. (2021) (99)
- Depression and anxiety in long-term survivors 5 and 10 years after cancer diagnosis (2019) (97)
- Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas (2014) (95)
- Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. (2013) (93)
- Neoadjuvant therapy for oesophagogastric cancer (2004) (93)
- Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. (2017) (90)
- Recent advances in multimodal treatment for gastric cancer: a review (2005) (90)
- Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance (2013) (88)
- Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center (2009) (86)
- The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT (2009) (86)
- ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer (2020) (84)
- Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. (2005) (82)
- Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. (2016) (80)
- Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer (2005) (80)
- Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. (2022) (79)
- Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program (2011) (77)
- Rectal cancer: MR imaging before neoadjuvant chemotherapy and radiation therapy for prediction of tumor-free circumferential resection margins and long-term survival. (2007) (77)
- Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. (2006) (77)
- Combined GADD45A and Thymidine Phosphorylase Expression Levels Predict Response and Survival of Neoadjuvant-Treated Gastric Cancer Patients (2005) (77)
- New agents on the horizon in gastric cancer (2017) (77)
- Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer (2003) (76)
- Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. (2006) (75)
- Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm (2021) (75)
- Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. (2008) (74)
- Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach? (2014) (74)
- Comorbid conditions and health-related quality of life in long-term cancer survivors—associations with demographic and medical characteristics (2018) (71)
- Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response (2008) (69)
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. (2011) (69)
- The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107 (2005) (68)
- Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter‐related infections in patients with haemato‐oncological diseases: a prospective observational study (2003) (68)
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study (2019) (68)
- Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients (2012) (68)
- Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. (2016) (67)
- International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus (2015) (66)
- Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer (2012) (64)
- Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial (2011) (64)
- Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (2011) (63)
- A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. (2014) (62)
- Limited resection and free jejunal graft interposition for squamous cell carcinoma of the cervical oesophagus (2009) (62)
- Fear of cancer recurrence across the survivorship trajectory: Results from a survey of adult long‐term cancer survivors (2019) (62)
- Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial (2005) (61)
- Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer (2011) (60)
- The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies (2008) (58)
- Age and gender differences in anxiety and depression in cancer patients compared with the general population. (2019) (57)
- FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma (2016) (56)
- Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival (2008) (56)
- The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor‐related survival in neoadjuvant treated locally advanced gastric cancer (2006) (55)
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. (2015) (54)
- Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. (2008) (51)
- DNA Repair Gene and MTHFR Gene Polymorphisms as Prognostic Markers in Locally Advanced Adenocarcinoma of the Esophagus or Stomach Treated with Cisplatin and 5-Fluorouracil-Based Neoadjuvant Chemotherapy (2011) (51)
- Prognostic and Putative Predictive Biomarkers of Gastric Cancer for Personalized Medicine (2013) (50)
- Induction Chemotherapy in Barrett Cancer: Influence on Surgical Risk and Outcome (2007) (50)
- [Diagnosis of and therapy for hepatocellular carcinoma]. (2013) (49)
- Value of functional imaging by PET in esophageal cancer. (2015) (48)
- Organotypic slice cultures of human gastric and esophagogastric junction cancer (2016) (48)
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer (2020) (47)
- Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). (2020) (46)
- The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib (2006) (46)
- Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. (2007) (46)
- Phenotyping of Tumor Biology in Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation, αvβ3 Expression, and Glucose Metabolism (2010) (46)
- Cetuximab plus weekly oxaliplatin/5FU/FA (FUFOX) in 1st line metastatic gastric cancer. Final results from a multicenter phase II study of the AIO upper GI study group (2007) (46)
- [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. (2018) (46)
- Assessment of Tumor Regression of Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy: Comparison of 2 Commonly Used Scoring Approaches (2014) (45)
- Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study (2018) (45)
- Primary and metastatic peritoneal surface malignancies (2021) (45)
- 3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer (2007) (45)
- Journal of Cancer Research and Clinical Oncology (2021) (44)
- 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. (2017) (44)
- Gastric cancer: surgery in 2011 (2011) (44)
- The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. (2008) (44)
- Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy—final results of the larynx organ preservation trial DeLOS-II (2018) (43)
- European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. (2008) (43)
- Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients (2008) (43)
- Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). (2014) (41)
- Erlotinib as 2nd and 3rd line monotherapy in patients with metastatic colorectal cancer. Results of a multicenter two-cohort phase II trial (2005) (41)
- Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases (2014) (41)
- HER2 testing in gastric cancer: results of a German expert meeting (2017) (41)
- Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). (2014) (40)
- VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study (2020) (40)
- Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer (2018) (40)
- A reliable risk score for stage IV esophagogastric cancer. (2013) (40)
- A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results (2005) (39)
- [Breast cancer in the early stage]. (2012) (39)
- Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial (2015) (38)
- ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer. (2018) (38)
- Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features (2007) (38)
- Internet-based perioperative exercise program in patients with Barrett’s carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomized-controlled trial (2017) (37)
- Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. (2015) (36)
- Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer (2020) (35)
- 14LBA Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) (2009) (34)
- Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial (2019) (34)
- Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor (2012) (34)
- Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG (2017) (34)
- [Current S3 guidelines on surgical treatment of gastric carcinoma]. (2012) (33)
- Impact of multidisciplinary tumor boards on diagnosis and treatment of esophageal cancer (2007) (32)
- Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial (2008) (32)
- Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy (2014) (32)
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study (2022) (32)
- Targeting the HGF/MET pathway in gastric cancer. (2014) (31)
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. (2019) (31)
- How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer? (2011) (31)
- Paclitaxel in the Neoadjuvant Treatment for Adeno carcinoma of the Distal Esophagus (AEG I). A Comparison of Two Phase II Trials with Long-Term Follow-Up (2008) (30)
- Death-Related Anxiety in Patients With Advanced Cancer: Validation of the German Version of the Death and Dying Distress Scale. (2016) (30)
- Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. (2016) (30)
- What treatment in 2017 for inoperable pancreatic cancers? (2017) (29)
- HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study (2021) (29)
- MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. (2013) (29)
- Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). (2018) (29)
- Chemotherapy for resectable microsatellite instability-high gastric cancer? (2020) (29)
- Multimodal treatment of esophageal cancer (2013) (28)
- Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer. (2011) (28)
- Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy. (2007) (27)
- Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis (2013) (26)
- Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. (2013) (25)
- CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. (2009) (25)
- Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial (2017) (24)
- Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adeno (2016) (24)
- Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research (2019) (24)
- High pretherapeutic thymidylate synthetase and MRP‐1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients (2010) (24)
- New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. (2010) (23)
- Atrial natriuretic peptide in acute hypoxia-exposed healthy subjects and in hypoxaemic patients. (1995) (23)
- The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. (2016) (22)
- Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial (2011) (22)
- A Multifactorial Histopathologic Score for the Prediction of Prognosis of Resected Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy (2014) (22)
- Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial. (2019) (22)
- Proteomic and metabolic prediction of response to therapy in gastric cancer. (2014) (22)
- The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma. (2015) (22)
- Risk for Depression and Anxiety in Long-Term Survivors of Hematologic Cancer (2019) (22)
- 7BA Trastuzumab added to standard chemotherapy (CT) as first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC): efficacy and safety results from the Phase III ToGA trial (2009) (21)
- Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results (2008) (20)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. (2021) (20)
- Symptoms and Needs of Head and Neck Cancer Patients at Diagnosis of Incurability - Prevalences, Clinical Implications, and Feasibility of a Prospective Longitudinal Multicenter Cohort Study (2016) (20)
- Management of Metastatic Gastric Cancer. (2017) (20)
- Individual Susceptibility Analysis Using Patient‐derived Slice Cultures of Colorectal Carcinoma (2017) (20)
- The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. (2019) (20)
- Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. (2018) (20)
- Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. (2006) (19)
- Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course (2021) (19)
- De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry (2020) (19)
- Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer. (2004) (19)
- A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients (2014) (19)
- In which context is physician empathy associated with cancer patient quality of life? (2018) (19)
- Factors associated with non‐participation and dropout among cancer patients in a cluster‐randomised controlled trial (2018) (19)
- Imagine a world without cancer (2014) (19)
- 6511 Human epidermal growth factor receptor 2 (HER2) in gastric cancer (GC): results of the ToGA trial screening programme and recommendations for HER2 testing (2009) (19)
- Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation (2015) (19)
- Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in patients with peritoneal metastasized colorectal, appendiceal and small bowel cancer (2020) (19)
- Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. (2009) (18)
- Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. (2018) (18)
- The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. (2018) (18)
- Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial (2014) (18)
- Evidence for PTGER4,PSCA, and MBOAT7 as risk genes for gastric cancer on the genome and transcriptome level (2017) (17)
- Insights into next developments in advanced gastric cancer (2016) (17)
- Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin (2021) (17)
- Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies. (2019) (17)
- Quality of life in survivors of hematological malignancies stratified by cancer type, time since diagnosis and stem cell transplantation (2018) (17)
- Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients (2011) (17)
- Symptoms and Needs of Patients with Advanced Lung Cancer: Early Prevalence Assessment (2019) (17)
- The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study. (2019) (16)
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO. (2020) (16)
- Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. (2017) (16)
- Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. (2022) (16)
- Gastric cancer adjuvant therapy. (2016) (16)
- Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction (2011) (16)
- PET/CT molecular imaging in abdominal oncology (2004) (16)
- SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer (2019) (15)
- Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians (2020) (15)
- Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas. (2013) (15)
- Covid-19 in outpatients—Is fever a useful indicator for SARS-CoV-2 infection? (2021) (15)
- Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome (2017) (15)
- Tumor-associated macrophages and individual chemo-susceptibility are influenced by iron chelation in human slice cultures of gastric cancer (2019) (15)
- Polypharmacy, limited activity, fatigue and insomnia are the most frequent symptoms and impairments in older hematological cancer survivors (70+): Findings from a register-based study on physical and mental health. (2019) (15)
- Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study (2014) (15)
- Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas (2010) (15)
- Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). (2012) (15)
- Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. (2005) (14)
- An open-label, multicenter biomarker-oriented phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer (2011) (14)
- Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) (2008) (14)
- HER2 positivity in advanced gastric cancer is comparable to breast cancer (2007) (14)
- Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. (2019) (14)
- [Curative vs palliative strategies in locoregional recurrence of gastrointestinal malignancies]. (2006) (14)
- Cetuximab in Combination with Capecitabine and Cisplatin as First-Line Treatment in Advanced Gastric Cancer: Randomized Controlled Phase III Expand Study (2012) (14)
- Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. (2008) (14)
- (Neo)-Adjuvant Chemo(-Radio) Therapy for Adenocarcinomas of the Gastroesophageal Junction and the Stomach in the West (2013) (13)
- Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus (2014) (13)
- Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. (2012) (13)
- Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma (2015) (13)
- PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. (2018) (13)
- Weekly docetaxel monotherapy for advanced gastric or esophagogastric junction cancer. Results of a phase II study in elderly patients or patients with impaired performance status. (2008) (13)
- Adjuvant Radiotherapy for Gastric Cancer - End of the Road? (2020) (13)
- Current treatment approach to locally advanced esophageal cancer: is resection mandatory? (2006) (13)
- Antibody-based targeted therapy for gastric cancer (2005) (13)
- Results of a Multimodal Therapy in Patients with Stage IV Barrett’s Adenocarcinoma (2008) (13)
- [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]. (2007) (12)
- Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/II trial (2005) (12)
- Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma. (2006) (12)
- Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. (2010) (12)
- 636PEFFICACY AND SAFETY OF MULTIPLE DOSES OF IMAB362 IN PATIENTS WITH ADVANCED GASTRO-ESOPHAGEAL CANCER: RESULTS OF A PHASE II STUDY. (2014) (12)
- Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study. (2018) (12)
- Remission of Paraneoplastic Dermatomyositis Associated with Hepatocellular Carcinoma under Prednisolone and Azathiopin, and Concommittant Sorafenib (2009) (11)
- IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial. (2015) (11)
- Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer – the multinational MATEO study (2017) (11)
- The association between an anxiety disorder and cancer in medical history. (2019) (11)
- Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. (2009) (11)
- Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. (2022) (11)
- To resect or not resect in metastatic gastric cancer: that is the question! (2012) (11)
- Survival with cetuximab/FOLFOX or cetuximab/FOLFIRI of patients with nonresectable colorectal liver metastases in the CELIM study. (2012) (11)
- Population-Based Patterns of Care in the First-Line Treatment of Patients with Advanced Esophagogastric Adenocarcinoma in Germany (2010) (11)
- Cetuximab with irinotecan/NA-FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomised multi-centre AIO phase II study (2008) (11)
- Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy (2021) (10)
- [Interdisciplinary psychoeducational intervention by oncologists proved helpful for cancer patients]. (2003) (10)
- Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma (2021) (10)
- Targeted and immunotherapy in the era of personalised gastric cancer treatment. (2021) (10)
- Phase III study (20050181) of panitumumab with FOLFIRI compared to FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer: preliminary safety results. (2008) (10)
- The evolving role of catumaxomab in gastric cancer (2008) (10)
- T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer. (2022) (10)
- SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study (2019) (10)
- Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU (2014) (9)
- Chemotherapy-Induced Nausea and Vomiting in the Treatment of Gastrointestinal Tumors and Secondary Prophylaxis with Aprepitant (2009) (9)
- [Follicular drug reaction from cetuximab: a common side effect in the treatment of metastatic colon carcinoma]. (2006) (9)
- [Preconditioning prior to visceral oncological surgery : A paradigm shift in visceral surgery?] (2018) (9)
- Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, as monotherapy in patients with locally advanced or metastatic pancreatic cancer (PC). (2006) (9)
- [HER2 testing in gastric cancer : Results of a meeting of German experts]. (2016) (9)
- [Current standards in the treatment of gastric cancer]. (2015) (9)
- 546PTUMOUR SHRINKAGE AND RESPONSE OUTCOMES DURING SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT. (2014) (9)
- Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma (2016) (8)
- Cetuximab and chemotherapy in the treatment of patients with initially “nonresectable” colorectal (CRC) liver metastases: Long-term follow-up of the CELIM trial. (2013) (8)
- Symptomatic Hyponatraemia Caused by Cylophosphamide (2009) (8)
- Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. (2022) (8)
- Definitive or neoadjuvant chemoradiotherapy for squamous cell oesophageal cancer? (2018) (8)
- [S3 guideline - diagnosis and treatment of gastric carcinoma: relevance for radiologic imaging]. (2012) (8)
- Spatial metabolomics identifies distinct tumor-specific subtypes in gastric cancer patients. (2022) (8)
- FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo (2021) (8)
- Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients (2020) (8)
- A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin (2019) (8)
- [Multimodal therapy of esophageal cancer]. (2008) (8)
- Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future (2018) (8)
- Proteomics in gastrointestinal cancer. (2006) (8)
- Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU: more than 20 years' experience at a single institution. (2014) (8)
- [Neoadjuvant therapy for squamous cell carcinoma of the esophagus]. (2005) (8)
- Influence of Taxanes on Treatment Sequence in Gastric Cancer (2019) (8)
- An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer. (2010) (7)
- [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures]. (2019) (7)
- 198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (2020) (7)
- Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010) (2021) (7)
- Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma (2015) (7)
- [Perioperative chemotherapy vs. surgery alone in resectable gastroesophageal carcinomas. Results of the MAGIC study]. (2006) (7)
- Gastrointestinal cancer: Over the RAINBOW—renaissance in antiangiogenesis (2015) (7)
- The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. (2013) (7)
- Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform. (2015) (7)
- [Diagnosis and treatment of gastric cancer]. (2010) (7)
- Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC) (2020) (7)
- Current status of immunotherapy in gastrointestinal malignancies (2020) (7)
- EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study. (2020) (7)
- Individualized neoadjuvant treatment strategy in adenocarcinoma of the esophago-gastric junction (AEG): Interim report on the MUNICON trial. (2004) (7)
- [Response prediction--early response evaluation. Consequences for surgical oncology]. (2006) (6)
- Three-weekly docetaxel (T) plus capecitabine (X) in 1st and 2nd line metastatic esophageal cancer (MEC): Final Results of the phase II DACAPO Trial (2005) (6)
- Gastrointestinal cancer: Salvage chemotherapy in gastric cancer—more than a straw? (2012) (6)
- 548PIMPACT OF BASELINE COVARIATES AND PRIOR THERAPY ON THE EFFICACY OF SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT. (2014) (6)
- Chances, risks and limitations of neoadjuvant therapy in surgical oncology (2016) (6)
- [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy]. (2011) (6)
- 1496TiP Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma (2020) (6)
- Phase I/II study of cetuximab, capecitabine and oxaliplatin (CAPOX) combined with standard radiotherapy (RTX) as neoadjuvant treatment of advanced rectal cancer (RC). (2006) (6)
- GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2019) (6)
- Randomised trial of capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (GemOx) in advanced pancreatic cancer. (2004) (6)
- PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study. (2011) (6)
- Two steps forward and one step back (2018) (6)
- Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View (2021) (6)
- Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET (2007) (6)
- Abstract 2615: Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ study (2018) (5)
- Perioperative and Palliative Chemotherapy for Esophageal Cancer (2015) (5)
- Depression and anxiety in older patients with hematological cancer (70+) - Geriatric, social, cancer- and treatment-related associations. (2019) (5)
- Will molecular target agents enable the multidisciplinary treatment in stage IV gastric cancer? (2017) (5)
- HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges (2011) (5)
- A Different Kind of Relapse: Ethanol as an Additive in Chemotherapy Formulations (2019) (5)
- An open-label, multicenter phase II trial of SUNITINIB for patients with chemorefractory metastatic gastric cancer (2010) (5)
- Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal (2021) (5)
- 195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) (2020) (5)
- Cetuximab, capecitabine, and oxaliplatin (Cet-CapOx) with concurrent radiotherapy (RT) in advanced rectal cancer (RC): Results of a phase I/II trial (2007) (5)
- Progress and challenges in gastroesophageal cancer. (2020) (5)
- PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma (2021) (5)
- Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts. (2020) (5)
- Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial (2018) (5)
- A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial (2012) (5)
- Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study. (2017) (5)
- EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial. (2016) (5)
- Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC). (2012) (5)
- Mistletoe treatment for cancer--promising or passé? (2014) (5)
- Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE‐3) (2021) (4)
- Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial. (2018) (4)
- Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2−advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW. (2020) (4)
- Gastric cancer – still many questions to be solved (2011) (4)
- Nivolumab for previously treated squamous oesophageal carcinoma. (2019) (4)
- Individualized indication for neoadjuvant treatment based on metabolic response Assessed by 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in adenocarcinoma of the esophago-gastric junction (AEG) (2005) (4)
- [Importance of PET in surgery of esophageal cancer]. (2014) (4)
- Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition (2021) (4)
- The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management (2012) (4)
- [Tumor markers and biomarkers in squamous cell cancer of the head and neck]. (2008) (4)
- Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study. (2012) (4)
- Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3. (2021) (4)
- ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) (2016) (4)
- Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF (2022) (4)
- Current standard and trends in oesophageal cancer. (2011) (4)
- Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study. (2019) (4)
- [Supportive Care and Information Needs of Cancer Survivors: A Comparison of Two Cohorts of Longterm Cancers Survivors 5 and 10 Years after Primary Cancer Diagnosis]. (2019) (4)
- Oxaliplatin plus 5FU/folinic acid (FUFOX regimen) in 1st line metastatic gastric cancer (MGC). Results of the Multicenter Phase II STOMOX Trial (2005) (4)
- 3518 POSTER Cetuximab with Irinotecan/FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomized multicenter AIO phase II study (2007) (4)
- Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom? (2021) (4)
- Perioperative chemotherapy with ECX +/- panitumumab in locally advanced gastroesophageal adenocarcinomas (GEA): A randomized study of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the German Cancer Society. (2015) (4)
- Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. (2020) (3)
- Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2017) (3)
- [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. (2009) (3)
- High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact. (2019) (3)
- Biomarkers related to fatty acid oxidative capacity are predictive for continued weight loss in cachectic cancer patients (2021) (3)
- ["Good advice is precious." The second opinion from the point of view of an interdisciplinary cancer therapy center]. (2007) (3)
- [Incidence and treatment of chemotherapy-induced nausea and emesis in gastrointestinal cancer]. (2014) (3)
- PD-0002KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB + FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS (2014) (3)
- [Treatment of gastric cancer]. (2014) (3)
- Outcomes of Patients with Squamous Cell Carcinoma of Esophagus who did not receive Surgical Resection after Neoadjuvant Radiochemotherapy (2015) (3)
- [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. (2019) (3)
- Young patients with cancer and a digital social network: the voice beyond the clinic (2020) (3)
- Perioperative Sicherheit der intraperitonealen Aerosolchemotherapie (2018) (3)
- Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction (2014) (3)
- Associations between the EGFR status as well as KRAS mutations and clinical outcome in colorectal cancer (CRC) patients (pts) treated with erlotinib monotherapy in 2nd or 3rd line—A study of the Arbeitsgemeinschaft Internistische (2008) (3)
- Hepatocellular carcinoma-united forces against a global killer. (2020) (3)
- Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study (2023) (3)
- The role of PET in predicting response to chemotherapy in oesophago-gastric cancer. (2011) (3)
- Possible individualized therapy by early assessment of response during neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma patients by 18-FDG-PET. (2006) (3)
- [Neoadjuvant chemotherapy or primary surgery for colorectal liver metastases. Pro adjuvant chemotherapy]. (2014) (3)
- [Gene expression analyses and their possible clinical benefit in head and neck cancer]. (2015) (3)
- Human tumor slice cultures for cancer research and drug testing (2017) (3)
- Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial (2022) (3)
- The evolving role of catumaxomab in gastric cancer. (2008) (3)
- 1495P FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Final results from the phase II RAMIRIS Study of the AIO (2020) (3)
- Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up. (2016) (3)
- Social networks for young patients with cancer: the time for system agility. (2019) (3)
- [Special situations of preconditioning and prehabilitation in oncological visceral surgery]. (2018) (3)
- [Pretherapeutic misclassification of esophageal cancer and adenocarcinoma of the esophagogastric junction : Possibilities and clinical consequences]. (2019) (2)
- 2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC (2015) (2)
- Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer. (2021) (2)
- [Neoadjuvant chemotherapy for gastric cancer. Frequent overtreatment or meaningful concept?] (2020) (2)
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: The RAMIRIS study. (2018) (2)
- Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients (2021) (2)
- FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. (2022) (2)
- Corrigendum to "2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer" [Eur J Cancer 63 (August 2016) 11-24]. (2016) (2)
- Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty (2019) (2)
- Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: A multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. (2022) (2)
- Treatment of colorectal cancer – ASCO 2009 (2009) (2)
- Final report of assessment of response to neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma patients by 18-FDG-PET (2006) (2)
- [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. (2015) (2)
- LBA-06IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer (2016) (2)
- Docetaxel, cisplatin and leucovorin/fluorouracil in first-line advanced gastric cancer and adenocarcinoma of the esophagogastric junction: Results of the phase II GASTRO-TAX-1 trial (2007) (2)
- CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial (2021) (2)
- Arguments for and against Centralization in Oncologic Visceral Medicine (2017) (2)
- GWAS meta-analysis of 16 790 patients with Barrett’s oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level (2022) (2)
- [Weight loss in cancer patients]. (2016) (2)
- The role of biologics in stomach cancer (2008) (2)
- [Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas]. (2011) (2)
- Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer (2022) (2)
- 1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO (2020) (2)
- [Systemic treatment of peritoneal metastases]. (2007) (2)
- Multidisziplinarität im Cancer Center (2010) (2)
- How to Create Evidence for the Integration of Local and Locoregional Treatments in Future Oncological Treatment Concepts? (2014) (2)
- (Neo-)Adjuvant radiochemotherapy in stage II/III rectal cancer (2011) (2)
- Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin. (2021) (1)
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study (2022) (1)
- Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer. (2018) (1)
- 664PPhase 1 Study of IMAB362 with immunomodulation in patients with advanced gastric cancer (2017) (1)
- Rectal cancer with synchronous liver metastases: leave it all in? When (not) to resect the primary? (2014) (1)
- 261 Association of T-cell–inflamed gene expression profile and PD-L1 status with efficacy of pembrolizumab in patients with esophageal cancer from KEYNOTE-180 (2020) (1)
- Correction: Covid-19 in outpatients—Is fever a useful indicator for SARS-CoV-2 infection? (2021) (1)
- Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (2022) (1)
- Study protocol: the OptiScreen-Study: optimized psycho-oncological care—from screening to intervention (2022) (1)
- Anti-angiogenesis: disappointment in localised oesophagogastric cancer. (2017) (1)
- Imagine a world without cancer (2014) (1)
- 6579 Cetuximab with Irinotecan/Folinic Acid/5-FU as first-line treatment in advanced gastric cancer: a prospective multi-center phase II study and additional biomarkers of the Arbeitsgemeinschaft Internistische Onkologie (2009) (1)
- Resectability and indication for chemotherapy in patients with colorectal liver metastases as assessed by medical oncologists and surgeons. (2012) (1)
- Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW. (2023) (1)
- Catumaxomab versus catumaxomab plus prednisolone in patients with malignant ascites due to epithelial cancer: results from the CASIMAS study (2012) (1)
- Metabolomic therapy response prediction in pretherapeutic tissue biopsies for trastuzumab in patients with HER2‐positive advanced gastric cancer (2021) (1)
- Basaloid Squamous Cell Carcinoma: A Rare Tumor at the Esophagogastric Junction and an Unexpected Durable Complete Response to FOLFOX-4 (2014) (1)
- [Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)]. (2008) (1)
- Standardized Diagnostics Including PET-CT Imaging, Bilateral Tonsillectomy and Neck Dissection Followed by Risk-Adapted Post-Operative Treatment Favoring Radio-Chemotherapy Improve Survival of Neck Squamous Cell Carcinoma of Unknown Primary Patients (2021) (1)
- Cisplatin and 5-Fluorouracil with or Without Epidermal Growth Factor Receptor Inhibition Panitumumab for Patients with Non-Resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Prospective, Open-Label, Randomised Phase 3 AIO/EORTC Trial (Power) (2019) (1)
- [Adjuvant therapy for colon cancer]. (2004) (1)
- Treatment of radiation-induced mucocutaneous toxicity (2012) (1)
- Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise-Evidence and Implications. (2023) (1)
- A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2014) (1)
- [Current Standard Diagnosis and Treatment of Colon Cancer]. (2017) (1)
- TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG) (2015) (1)
- Catumaxomab: Pharmacodynamic and pharmacokinetic data from phase IIIb CASIMAS study in patients with malignant ascites. (2012) (1)
- Side effect management during treatment of gastrointestinal (GI) cancers (2011) (1)
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023) (1)
- SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells (2020) (1)
- P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer (2020) (1)
- Weekly cetuximab (CET) plus oxaliplatin (OX), infusional 5-fluorouracil (5-FU) and radiation therapy (RT) as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A phase I study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2009) (1)
- Metabolic response assessment and PET-guided treatment of esophageal cancer. (2020) (1)
- Predictors for thromboembolism in patients with cholangiocarcinoma (2021) (1)
- The role of panitumumab in combination with ECX in perioperative chemotherapy of unselected patients with locally advanced gastroesophageal adenocarcinomas: Randomized phase II study of the German Cancer Society. (2015) (1)
- [Which tumor patients profit from interdisciplinary psychoeducation in the framework of a tumor therapy?]. (2007) (1)
- Connections are clearly more complexy. (2013) (1)
- Impact of molecular alterations on quality of life and prognostic understanding over time in patients with incurable lung cancer: a multicenter, longitudinal, prospective cohort study (2021) (1)
- [Value of postoperative radiochemotherapy after completely resected gastric cancer not definitive despite negative overall results of the ARTIST trial]. (2012) (1)
- PCN67 MANAGEMENT OF MALIGNANT ASCITES IN GERMANY—TREATMENT PATTERNS, RESOURCE CONSUMPTION, AND COSTS (2010) (1)
- Cervical squamous cell carcinoma of the esophagus-a unique series of limited resection and free jejunal graft interposition after neoadjuvant RCTx in 94 patients (2007) (1)
- European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions (2022) (1)
- 64. EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION EudraCT number 2014-000722-38; NCT02205047 (2016) (1)
- 235 INVITED Molecular Imaging for Response Monitoring in Esophageal Cancer (2011) (1)
- Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe. (2023) (1)
- Metastatic esophagogastric adenocarcinomas (EGA): Treatment, prognosis, and pretherapeutic selection options. (2014) (1)
- [Neoadjuvant and perioperative treatment of gastric cancer, current studies and new biomarkers]. (2021) (1)
- [What is confirmed in the treatment of colon cancer?] (2022) (1)
- Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis (2021) (1)
- ESOPEC: A prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy to neoadjuvant chemoradiation in patients with adenocarcinoma of the esophagus (NCT02509286). (2016) (1)
- Treatment of oesophageal cancer - Stressing the patient perspective. (2017) (1)
- [Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours]. (2005) (1)
- Metabolic imaging predicts response and prognosis in neoadjuvant treated, locally advanced gastric cancer: Final results of a prospective study (2007) (1)
- Combinations of Platinum Compounds and Ionizing Radiation (2006) (1)
- Years CESAR Anticancer Drug Research – The 7 th CESAR Annual Meeting 2009 (0)
- Cetuximab with irinotecan/FA/5-FU as first-line treatment in advanced gastro esophageal cancer: A prospective multi-center and biomarker-oriented phase II study (2010) (0)
- 2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC) (2015) (0)
- Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study (2022) (0)
- Chemotherapy and Targeted Therapy (2014) (0)
- Abstract 2100: Resistance of gastric carcinoma cells towards c-met inhibition is mediated by compensatory HER3 upregulation involving SATB1 and PKC (2019) (0)
- Impact of pathologic complete response to preoperative docetaxel-based chemotherapy on disease-free survival in esophagogastric adenocarcinoma. (2013) (0)
- Length polymorphism in the promoter of the thymidylate synthase (TS) gene is associated with prognosis but not with response in neoadjuvant treated locally advanced (NTLA) gastric cancer (GC) (2004) (0)
- Individual hematotoxicity prediction of further chemotherapy cycles by dynamic mathematical models in patients with gastrointestinal tumors. (2023) (0)
- Phase I trial of continous infusion 5-fluorouracil (CI-5FU) and escalating doses of oxaliplatin (OXA) given weekly with concurrent radiation (RT) in locally advanced esophageal squamous cell carcinoma (ESCC) (2005) (0)
- VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. (2019) (0)
- Imaging in gastro-esophageal cancer – the EORTC image study (2009) (0)
- Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial (2018) (0)
- Single agent cetuximab induces a decrease in the tumor glucose-uptake measured by 18F-fluorodeoxyglucose positron emission tomography in advanced squamous cell carcinoma of the esophagus (2008) (0)
- Effect of PD-1 inhibition on macrophage population in human tissue cultures. (2023) (0)
- Novel approaches to treat gastric cancer in Europe. (2017) (0)
- Length polymorphism in the promoter of the thymidylate synthase (TS) gene is associated with prognosis but not with response in neoadjuvant treated locally advanced (NTLA) gastric cancer (GC). (2004) (0)
- Oligometastases of Gastrointestinal Cancer Origin (2017) (0)
- Advanced gastric cancer. Status quo of systemic therapy and influence on the quality of life (2016) (0)
- Intestinal Symptoms and Quality of Life after Multimodal Therapy of Rectal Cancer (2009) (0)
- More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward. (2018) (0)
- Acknowledgement to Reviewers (2015) (0)
- Contents of Forthcoming Issues (2014) (0)
- Efficacy of a brief manualized intervention Managing Cancer and Living Meaningfully (CALM) adapted to German cancer care settings: study protocol for a randomized controlled trial (2015) (0)
- Current Standards and New Trends in Oesophageal Cancer (2012) (0)
- Questions About a Clinical Trial Evaluating the Addition of Cetuximab to Definitive Chemoradiation Therapy With Paclitaxel and Cisplatin for Patients With Esophageal Cancer. (2018) (0)
- Maintenance of quality of life (QoL) and general health state in patients with malignant ascites during treatment with the trifunctional antibody catumaxomab: results from the phase III b CASIMAS trial (2012) (0)
- Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. (2011) (0)
- Mistletoe Treatment for Cancer (2014) (0)
- IS1-3PERSPECTIVE OF SYSTEMIC CHEMOTHERAPY FOR GASTRIC CANCER IN EUROPE (2014) (0)
- [HER2 testing in gastric cancer - results of a German expert meeting]. (2016) (0)
- Gastric Cancer in Autoimmune Gastritis: A Case–Control Study from the Star Project on Gastric Cancer Research (2017) (0)
- Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind? (2020) (0)
- EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study. (0)
- Esophagogastric Adenocarcinoma Erythropoietin-alfa During Neoadjuvant Chemotherapy for Locally Advanced (2013) (0)
- Identification of predictive response and resistance factors to targeted therapy in gastric cancer using a systems medicine approach (2016) (0)
- Accomplishments in 2008 in the adjuvant treatment of rectal cancer. (2009) (0)
- Initial FDG uptake in patients with adenocarcinomas of the esophagogastric junction (AEG): Is it correlated to tumor localization and to patients' survival? (2007) (0)
- [ASCO update 2006--highlights of the 42. meeting of the American Society of Clinical Oncology/ASCO 2006]. (2006) (0)
- Targeting HER2 for localised oesophageal cancer (2022) (0)
- Multimodale Therapie des sophaguskarzinoms (2008) (0)
- Salvage chemotherapy for advanced gastric cancer: more than a false hope? (2017) (0)
- PG 7.03 Optimizing neoadjuvant chemotherapy through the use of early response evaluation (PET) (2012) (0)
- Su1129 – Predictive Significance of Endosonographic (EUS) Staging in Locally Advanced Gastric (GC) Or Gastroesophagealjunction (AEG) Adenocarcinoma: Analysis of Data from a Perioperative Aio-Cao Phase Ii Study (2019) (0)
- Changing paradigms in adjuvant treatment of colorectal cancer. (2018) (0)
- Esophageal cancer. (1997) (0)
- 100P Patient-derived tissue cultures of esophagogastric-junction cancer (EGJC) and gastric cancer (GC): An ex vivo model to study individual response of immunotherapy (2020) (0)
- 1053 Indicators of high chemotherapy-induced nausea and vomiting treatment costs in German cancer centers (2003) (0)
- [Not Available]. (2015) (0)
- Quantitative study using 18F-FDG in patients with locally advanced adenocarcinoma of the esophago-gastric junction during induction chemotherapy (2009) (0)
- Cancer prevention in females with and without obesity: Does perceived and internalised weight bias determine cancer prevention behaviour? (2022) (0)
- Predictive Value of Preoperative Endoscopic Ultrasound (EUS) After Neoadjuvant Chemotherapy in Locally Advanced Esophagogastric Cancer - Data From a Randomized German Phase II Trial. (2022) (0)
- 422P Age and pathological complete response after neoadjuvant chemoradiation (CRT) with or without oxaliplatin in locally advanced rectal cancer (LARC): Individual patient data (IPD) meta-analysis of three randomised trials (RTs) (2020) (0)
- Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis (2021) (0)
- Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies—the role of HAS2, SHB and HBEGF (2022) (0)
- Supportive treatment – an integral part of cancer care (2012) (0)
- Influence of chemotherapy related genetic polymorphisms and FDG-PET on response and prognosis of locally advanced neoadjuvant treated adenocarcinomas of the esophagus (AEG I). (2006) (0)
- Histopathological response to neoadjuvant chemotherapy is predictive for prognosis in locally advanced gastroesophageal cancer (2016) (0)
- Results of the REGATTA trial on surgical therapy of limited metastatic gastric cancer: open issues and future perspectives (2016) (0)
- PD-005Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC) (2016) (0)
- Phase-I study for definitive radiochemotherapy (RCT) with paclitaxel and cisplatin in locally advanced squamous cell cancers of the suprabifurcal oesophagus (2006) (0)
- Prognostic factors for the efficacy of catumaxomab in patients (pts) with malignant ascites (MA): Meta-analysis from two phase III studies. (2013) (0)
- [Novel pharmaceutical treatment approaches for gastric cancer]. (2017) (0)
- Precision Medicine (2020) (0)
- Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced gastroesophageal cancer: A retrospective pooled analysis of individual patient data. (2014) (0)
- Exploratory biomarker assessment in the Trastuzumab for Gastric Cancer (ToGA) study. (2011) (0)
- [Structured patient education in oncology. A prospective study for implementing and effectiveness of interdisciplinary psycho-educational group intervention at a German university clinic]. (2002) (0)
- Real life experience with selective internal radiation therapy (SIRT) as part of multimodality treatment of advanced hepatocellular carcinoma (HCC) (2018) (0)
- Severe hypovitaminosis D in metastatic gastric cancer patients from the Northern and Southern hemispheres: Data from the EXPAND phase III trial (2019) (0)
- Organotypic slice cultures of human gastric cancer (GC) and esophagogastric junction adenocarcinoma (AEG): A new technology to study treatment response, resistance, and tumor heterogeneity. (2015) (0)
- GALAD score correlates with therapy response for transarterial and systemic therapies in patients with hepatocellular carcinoma (2022) (0)
- Survival after primary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (FFCD ACHBTH AURC 9002 trial and EORTC Intergroup trial 40983). (2019) (0)
- Atrial n natriuretic p peptide iin a acute h hypoxia-exposed h healthy s subjects and iin h hypoxaemic p patients (1995) (0)
- Update Skills in Head and Neck Surgery and Oncology 2015 (2015) (0)
- Combining Platinums in Gastric Cancer (2009) (0)
- New prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma (2020) (0)
- A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. (2013) (0)
- Acknowledgement to Reviewers (2007) (0)
- IGICS: JGA Keynote Program. The 13th International Gastrointestinal Consensus Symposium (GICS). Gastrointestinal Disease: From Basics to Translational and Clinical Research: Abstracts (2020) (0)
- Prognostic score utilizing glypican-3 serum levels for the prediction of 6-month outcome after transarterial therapies for patients with intermediate stage hepatocellular carcinoma (2020) (0)
- Anti-angiogenics in Gastroesophageal Cancer (2019) (0)
- PCN60 CLINICAL AND ECONOMIC ASPECTS OF THE MANAGEMENT OF PATIENTS WITH MALIGNANT ASCITES—RESULTS OF A PILOT STUDY (2008) (0)
- IS4–3HOW TO PROLONG OVERALL SURVIVAL WITH MAINTAINING QUALITY OF LIFE (2013) (0)
- Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric cancer – the multinational MATEO study (2017) (0)
- [Erratum to: Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma]. (2020) (0)
- Precision Medicine for Visceral Cancer: Does the Future Lie in Molecular Stratification? (2020) (0)
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in HER-2-overexpressing metastatic gastro-esophageal cancer (GC): A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (2015) (0)
- A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial (2012) (0)
- Metabolic Heterogeneity Affects Trastuzumab Response and Survival in HER2-Positive Advanced Gastric Cancer (2022) (0)
- Current Therapeutic Options for GC (2014) (0)
- Lack of oxaliplatin dose adjustment is correlated with an increased frequency of oxaliplatin-induced neuropathy in obese patients with metastatic colorectal cancer (mCRC) (2016) (0)
- Prediction o f R esponse t o P reoperative C hemotherapy i n Gastric C arcinoma b y M etabolic I maging: Results o f a P rospective T rial (2003) (0)
- [Vitamin D and omega-3 fatty acid supplementation does not reduce the cancer and cardiovascular risk]. (2019) (0)
- ESMO guideline of esophago-gastric cancer. (2018) (0)
- [Multidisciplinary treatment for adult soft tissue sarcoma]. (2009) (0)
- Towards risk-adapted perioperative treatment of gastroesophageal cancer. (2018) (0)
- Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study. (2022) (0)
- Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer (2018) (0)
- Quality of life in patients with malignant ascites during catumaxomab treatment: Results from the CASIMAS trial. (2012) (0)
- Oncology in Europe. (2023) (0)
- XPC 939 and XRCC3 polymorphisms as prognostic markers in locally advanced esophageal and gastric adenocarcinoma treated with cisplatin and 5-FU based neoadjuvant chemotherapy (2009) (0)
- Phase 1 to 3 of the update of the EORTC Quality of Life Gastric module QLQ-STO22 (2019) (0)
- 629PLAPATINIB VERSUS LAPATINIB PLUS CAPECITABINE AS SECOND-LINE TREATMENT IN HER2-OVEREXPRESSING METASTATIC GASTRO-ESOPHAGEAL CANCER (GC): A RANDOMIZED PHASE II TRIAL OF THE ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE (AIO). (2014) (0)
- Is primary surgery without preoperative chemotherapy the best treatment option for signet ring cell esophagogastric adenocarcinomas (2014) (0)
- Update Skills in Head and Neck Surgery and Oncology 2015 (2015) (0)
- GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study (2019) (0)
- Risk factors for cancer-related venous thromboembolism in ambulatory patients. (2014) (0)
- Screening versus multidimensional assessment of symptoms and psychosocial distress in cancer patients from the time of incurability (2023) (0)
- Dickkopf-Related Protein 1 as Response Marker for Transarterial Chemoembolization of Hepatocellular Carcinomas (2022) (0)
- Changing the landscape of European School of Oncology–European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic (2022) (0)
- Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC). (2017) (0)
- P-81 phase I-II of the update of the EORTC quality of life gastric module QLQ-STO22 (2020) (0)
- Internet-based perioperative exercise program in patients with Barrett’s carcinoma scheduled for esophagectomy [iPEP - study] a prospective randomized-controlled trial (2017) (0)
- Physical and psychosocial factors associated with sexual satisfaction in long-term cancer survivors 5 and 10 years after diagnosis (2023) (0)
- [New angiogenesis inhibitor Ramucirumab: longer survival and better symptom control]. (2015) (0)
- Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition (2021) (0)
- SP145 PET imaging in upper GI Cancer – past experience and current EORTC initiatives (2009) (0)
- Antibody-Drug Conjugates as a Targeted Therapeutic Approach Across Entities in Oncology. (2023) (0)
- Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3). (2019) (0)
- SP-0212: Against the motion (2014) (0)
- 2nd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of rectal cancer (vol 63, pg 11, 2016) (2016) (0)
- Trastuzumab with chemotherapy in untreated HER2-positive advanced or metastatic gastric cancer (2009) (0)
- Maintenance of Quality of Life in Patients with Malignant Ascites During Treatment with the Trifunctional Antibody Catumaxomab: Results from the Phase III B Casimas Trial (2012) (0)
- Real-life experience with selective internal radiation therapy (SIRT) in multimodality treatment of advanced hepatocellular carcinoma (HCC) (2018) (0)
- [Treatment of gastric cancer]. (2008) (0)
- The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally (2022) (0)
- Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2021) (0)
- The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally (2022) (0)
- Hot Topics Gastroenterologie (2019) (0)
- Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer (2022) (0)
- Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty (2020) (0)
- Review 3 rd St . Gallen EORTC Gastrointestinal Cancer Conference : Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer (2017) (0)
- Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer (2023) (0)
- PCN9 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)—OUTCOMES OF PROPHYLACTIC CARE AND COSTS IN GERMAN CANCER CENTERS (2003) (0)
- [Pancreatic carcinoma: progress in therapy]. (2004) (0)
- Impact of the trifunctional antibody catumaxomab followed by systemic chemotherapy (CTX) on overall survival (OS): Results of a subgroup analysis in patients (pts) with relapsed ovarian cancer (OC) and malignant ascites (MA). (2013) (0)
- Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation. (2022) (0)
- 416. BIOMARKER IDENTIFICATION FOR CHEMOTHERAPY RESPONSE PREDICTION IN BARRETT’S CARCINOMA PATIENTS BY AN INFLAMMATORY-RELATED PLASMA PROTEIN PROFILING (2022) (0)
- [Comments on the statement of the German Society of Pathology (DGP) on clinical studies from a clinical perspective]. (2013) (0)
- Changes in the tumor glucose-uptake measured by 18F-FDG PET with two weeks of single-agent cetuximab in localized squamous cell carcinoma of the esophagus. (2013) (0)
- The value of a classification of histopathological response by residual tumor cells in patients with neoadjuvant treated esophageal squamous cell carcinomas (2006) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2022) (0)
- Staging of esophageal adenocarcinoma by CT, PET, and other modalities (2015) (0)
- Current and future strategies in the treatment of esophageal cancer (2021) (0)
- Acknowledgement to Reviewers (2016) (0)
- 1670MO Validation of a new risk-assessment model for prediction of venous thromboembolism in cancer outpatients: The ONKOTEV score (2021) (0)
- Abstract 6770: Spatial characterization of immune microenvironment from early onset metastatic colorectal cancer (EOmCRC) showed a dual prognostic role for IDO1 expression (2023) (0)
- P Phase 1 Study of IMAB 362 with immunomodulation in patients with advanced gastric cancer (2017) (0)
- Toward a Routine Assessment of Visceral Adipose Tissue Volume from Computed Tomographic Data (2020) (0)
- Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial (2023) (0)
- INVITED UPDATE PET/CT molecular imaging in abdominal oncology (2004) (0)
- SP-0022 New systemic treatments in non-metastasised oesophageal cancer (2022) (0)
- Prospective evaluation of FDG-PET for prediction of response and survival in AEG I/II (uT3cNany cM0) (2006) (0)
- Should chemotherapy-free treatment be offered for advanced oesophageal squamous-cell carcinoma? (2022) (0)
- Gene expression analysis in association with response and survival of neoadjuvant treated gastric cancers patients (2004) (0)
- Randomized controlled phase II trial of S-1 maintenance therapy in Caucasian population with metastatic esophagogastric cancer– the multinational MATEO study (2016) (0)
- AEG I and II: Is It One Tumor Entity? (2008) (0)
- Medical Oncology Education in Europe: Equipping Medical Oncologists to Provide the Best Care for Patients with Cancer (2023) (0)
- Addition of the monoclonal Epidermal Growth Factor (EGF) receptor antibody cetuximab (E) to cisplatin/5-FU (CF) versus CF in 1st line Metastatic Squamous Cell Carcinoma of the esophagus (MESCC): First results of the phase II oesotux trial (2008) (0)
- Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS - a randomised controlled multicentre trial (ISRCTN30964555) (2012) (0)
- [Current standards in the treatment of gastric cancer]. (2015) (0)
- Psychosocial aftercare of adolescent and young adult cancer survivors in Germany: Awareness, utilisation, satisfaction and associated factors (2021) (0)
- Metabolic response-guided treatment individualization in neoadjuvant therapy of locally advanced adenocarcinoma of the esophagogastric junction (AEG) (2007) (0)
- A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results. (2019) (0)
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (2022) (0)
- Validation of a risk-assessment score for prediction of venous thromboembolism in cancer outpatients receiving active treatments: ONKOTEV-2 trial (2016) (0)
- Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer (2023) (0)
- How does physician empathy interact with patient emotional skills to predict patient quality of life (2016) (0)
- Response-adapted treatment stratification in oesophago-gastric cancer. (2018) (0)
- Polymorphisms in the nucleotide excision repair genes ERCC1 and ERCC2 and association with response and prognosis in neoadjuvant treated gastric cancer patients (2007) (0)
- A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients (2014) (0)
- Front & Back Matter (2020) (0)
- Experiences with hypofractionated radiotherapy in combination with systemic or intraarterial chemotherapy: Report of 3 sequential phase I/II-studies (2007) (0)
- Population-Based Patterns of Care in the 1 st Line Treatment of Patients with Advanced Esophagogastric Adenocarcinoma in Germany Populations (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Florian Lordick?
Florian Lordick is affiliated with the following schools:
